Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer
JR Hecht, TR Reid, CR Garrett, JT Beck… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: To evaluate feasible doses of weekly everolimus and irinotecan given with cetuximab
for previously treated metastatic colorectal cancer (mCRC). Patients and Methods: Adults …
for previously treated metastatic colorectal cancer (mCRC). Patients and Methods: Adults …
Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
S Sharma, T Reid, S Hoosen, C Garrett… - Journal of Clinical …, 2009 - ascopubs.org
e15115 Background: The PI3K/AKT/mTOR pathway is frequently dysregulated in colorectal
cancer (Cancer Res 2005; 65: 11227). In a phase I study in patients with advanced solid …
cancer (Cancer Res 2005; 65: 11227). In a phase I study in patients with advanced solid …
Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102.
B Myre, M Yu, J Picus, JA Bufill, WA Harb… - Journal of Clinical …, 2011 - ascopubs.org
523 Background: Preclinically, mTOR and EGFR inhibitors are synergistic. We hypothesize
that the mTOR inhibitor RAD001 would enhance efficacy and prevent resistance when …
that the mTOR inhibitor RAD001 would enhance efficacy and prevent resistance when …
Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomized phase III trial (EPIC)
A Sobrero, W Scheithauer, J Maurel… - Journal of Clinical …, 2005 - ascopubs.org
3580 Background: The EPIC trial is a randomized phase III study comparing cetuximab plus
irinotecan to irinotecan in 2nd-line metastatic, EGFR-expressing colorectal cancer (CRC) …
irinotecan to irinotecan in 2nd-line metastatic, EGFR-expressing colorectal cancer (CRC) …
[HTML][HTML] Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer
H Mrabti, C De la Fouchardiere… - Journal of Cancer …, 2009 - journals.lww.com
Aim: The aim of the present study was to compare the efficacy and safety of weekly versus
an every 2-week administration of cetuximab in association with irinotecan in patients with …
an every 2-week administration of cetuximab in association with irinotecan in patients with …
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan …
K Ng, J Tabernero, J Hwang, E Bajetta, S Sharma… - Clinical Cancer …, 2013 - AACR
Purpose: Dysregulation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is seen
in 40% to 60% of patients with colorectal cancer. Everolimus, an oral inhibitor of mTOR …
in 40% to 60% of patients with colorectal cancer. Everolimus, an oral inhibitor of mTOR …
Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients …
N Moosmann, L Fischer von Weikersthal… - Journal of Clinical …, 2010 - ascopubs.org
3540 Background: Cetuximab combined with 5-fluorouracil/folinic acid plus irinotecan or
oxaliplatin has shown activity in the treatment of mCRC. This randomized phase II trial …
oxaliplatin has shown activity in the treatment of mCRC. This randomized phase II trial …
[HTML][HTML] Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group …
M Borner, D Koeberle, R Von Moos, P Saletti… - Annals of oncology, 2008 - Elsevier
Background To determine the activity and tolerability of adding cetuximab to the oxaliplatin
and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer …
and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer …
Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)
Y Abubakr, C Eng, L Wong, V Pautret… - Journal of Clinical …, 2006 - ascopubs.org
3556 Background: EPIC is a randomized phase III study comparing cetuximab plus
irinotecan to irinotecan in second-line metastatic, EGFR-expressing mCRC patients …
irinotecan to irinotecan in second-line metastatic, EGFR-expressing mCRC patients …
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study …
V Heinemann, LF von Weikersthal… - Journal of Clinical …, 2008 - ascopubs.org
4033 Background: Cetuximab combined with 5-fluorouracil/folinic acid (5-FU/FA) plus
irinotecan or oxaliplatin has shown activity in the treatment of mCRC. This randomized trial …
irinotecan or oxaliplatin has shown activity in the treatment of mCRC. This randomized trial …